Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1783-1789

  He, Xiaoping ^a   Khurana, Ashwani ^a   Roy, Debarshi ^a   Kaufmann, Scott ^b   Shridhar, Viji ^a  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Bim; HSulf 1; ovarian cancer; tumorigenicity

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; SULFATASE; SULFATASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OV202 CELL LINE; OVARY CANCER; PLASMID; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKOV3 CELL LINE; TUMOR GROWTH; WESTERN BLOTTING;

BIM; HSULF-1; OVARIAN CANCER; TUMORIGENICITY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; SULFOTRANSFERASES; TUMOR BURDEN;

EID: 84905735682     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28818     Document Type: Article

References (23)

1. Narita K, Chien J, Mullany SA, et al. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 2007; 282: 14413-20.
2. Lamanna WC, Frese MA, Balleininger M, et al. Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem 2008; 283: 27724-35.
3. Lai JP, Chien J, Strome SE, et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004; 23: 1439-47.
4. Narita K, Staub J, Chien J, et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006; 66: 6025-32.
5. Lai JP, Yu C, Moser CD, et al. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 2006; 130: 2130-44.
6. Staub J, Chien J, Pan Y, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 2007; 26: 4969-78.
7. Lai J, Chien J, Staub J, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003; 278: 23107-17.
8. He X, Ota T, Liu P, et al. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010; 70: 3109-18.
9. Taylor RC, Cullen SP, Martin SJ,. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-41.
10. Adams JM, Cory S,. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488-96.
11. Akiyama T, Dass CR, Choong PF,. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009; 8: 3173-80.
12. Grãos M, Almeida AD, Chatterjee S,. Growth-factor-dependent phosphorylation of Bim in mitosis. Biochem J 2005; 388: 185-94.
13. Deng J, Shimamura T, Perera S, et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007; 67: 11867-75.
14. Adams JM, Cory S,. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-37.
15. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005; 7: 227-38.
16. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14.
17. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132: 875-86.
18. Piñon JD, Labi V, Egle A, et al. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2008; 27 (Suppl 1): S41-S52.
19. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007; 109: 271-80.
20. Egle A, Harris AW, Bouillet P, et al. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-9.
21. Luciano F, Jacquel A, Colosetti P, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785-93.
22. Pinato DJ, Graham J, Gabra H, et al. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev 2013; 39: 153-60.
23. Witham J, Valenti MR, De-Haven-Brandon AK, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007; 13: 7191-8.